化剂环胺在增强抗瘤免疫力的作用
Benjamin D Gephart1,2, Don W Coulter2,3,4, Joyce C Solheim1,2,5,6
1Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
International journal of molecular sciences
|July 12, 2025
概括
环胺 (CPX) 是一种化剂,在瘤微环境中显示出强大的免疫调节作用. 低剂量计量学CPX可以增强抗瘤免疫力,并与检查点抑制剂等免疫疗法协同作用.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 环胺 (CPX) 是一种用于癌症治疗的化剂.
- 在瘤微环境 (TME) 中,CPX表现出免疫调节效应.
- 这些影响包括耗尽调节性T细胞 (Tregs) 和触发免疫细胞死亡 (ICD).
研究的目的:
- 为了探索环胺的免疫调节特性.
- 为了研究低剂量计量 CPX 与免疫疗法结合的疗效.
- 评估CPX在克服免疫检查点抑制剂耐药性的潜力.
主要方法:
- 对临床前模型和人类临床试验的审查.
- 对CPX对免疫抑制细胞和抗原呈现的影响的分析.
- 对计量学剂量表与最大耐受剂量的研究.
主要成果:
- CPX可以选择性地消耗免疫抑制调节T细胞 (Tregs).
- CPX触发免疫细胞死亡 (ICD) 并增强抗原呈现.
- 低剂量计量 CPX 显示了与免疫疗法结合的潜力.
结论:
- 环胺具有显著的免疫调节能力.
- 计量 CPX 调度提供了一种增强抗瘤免疫力的策略.
- CPX可能会改善对免疫疗法的反应,包括检查点抑制剂.
相关概念视频
Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mutagenicity and Carcinogenicity
1.4K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.4K
Combined Effects of Drugs: Synergism
4.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


